NXP logo

NXP Stock News & Sentiment

New S32K5 microcontroller family advances zonal SDV architectures and extends the NXP CoreRide platform
New S32K5 microcontroller family advances zonal SDV architectures and extends the NXP CoreRide platform
New S32K5 microcontroller family advances zonal SDV architectures and extends the NXP CoreRide platform
NXP
globenewswire.comMarch 11, 2025

NUREMBERG, Germany, March 11, 2025 (GLOBE NEWSWIRE) -- EMBEDDED WORLD -- NXP Semiconductors N.V. (NASDAQ: NXPI), the trusted partner for innovative solutions in the automotive market, today unveiled its new S32K5 family of automotive microcontrollers (MCU), the automotive industry's first 16nm FinFET MCU with embedded magnetic RAM (MRAM) . The S32K5 MCU family will extend the NXP CoreRide platform with pre-integrated zonal and electrification system solutions for scalable software-defined vehicle (SDV) architectures.

NXP Semiconductors Announces Quarterly Dividend
NXP Semiconductors Announces Quarterly Dividend
NXP Semiconductors Announces Quarterly Dividend
NXP
globenewswire.comMarch 6, 2025

EINDHOVEN, The Netherlands, March 06, 2025 (GLOBE NEWSWIRE) -- As part of its ongoing capital return program, NXP Semiconductors N.V. (NASDAQ: NXPI) today announced that its board of directors has approved the payment of an interim dividend. The actions are based on the continued and significant strength of the NXP capital structure, and the board's confidence in the company's ability to drive long-term growth and strong cash flow.

Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
NXP
businesswire.comMarch 5, 2025

NEW YORK--(BUSINESS WIRE)---- $NVCT #Cancerstocks--Market News Alerts Reports: Nuvectis Pharma (NASDAQ: NVCT)* announced today that new independent research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University) has demonstrated the superior efficacy of NXP900 when combined with osimertinib (Tagrisso®) in EGFR-mutated non-small cell lung cancer (NSCLC) models. The peer-reviewed study, published in Molecular Cancer Research, demonstrated that the combination therapy led to dec.

NXP: Acquisition Of TTTech Auto Acquisition Boosts SDV Market Offering
NXP: Acquisition Of TTTech Auto Acquisition Boosts SDV Market Offering
NXP: Acquisition Of TTTech Auto Acquisition Boosts SDV Market Offering
NXP
seekingalpha.comFebruary 24, 2025

NXP's acquisition of TTTech Auto enhances its SDV offerings by integrating safety-critical software, reducing reliance on external partners, and strengthening its competitive position. The SDV market is rapidly growing, driven by demand for advanced autonomous features, predictive maintenance, and OTA updates, benefiting NXP's semiconductor solutions. NXP's strong ADAS application portfolio, high AI compute performance, and extensive software partner network position it well to capitalize on the expanding SDV market.

NXP Agrees to Acquire Edge AI Pioneer Kinara to Redefine the Intelligent Edge
NXP Agrees to Acquire Edge AI Pioneer Kinara to Redefine the Intelligent Edge
NXP Agrees to Acquire Edge AI Pioneer Kinara to Redefine the Intelligent Edge
NXP
globenewswire.comFebruary 10, 2025

Enhances NXP's leading processing portfolio with cutting edge NPUs and AI software, driving intelligent system solutions across the industrial and automotive edge markets. Delivers high-performance neural network processing with advanced generative AI to create transformative edge use cases.

Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback
Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback
Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback
NXP
seekingalpha.comFebruary 6, 2025

The company's stock dropped due to disappointing phase 1b results for NXP800 in ARID1a-mutated ovarian cancer, but higher dosing may improve outcomes in Q2 2025. The company is also advancing NXP900 for YES1/SRC-expressing solid tumors, with promising early data showing no dose-limiting toxicities. The global ovarian cancer market is expected to reach $11.18 billion by 2029.

NXP Semiconductors: I'm Staying On Hold Post Earnings
NXP Semiconductors: I'm Staying On Hold Post Earnings
NXP Semiconductors: I'm Staying On Hold Post Earnings
NXP
seekingalpha.comFebruary 5, 2025

NXP Semiconductors (NASDAQ: NXPI) remains a hold due to ongoing industry slump and failure to meet growth targets set in 2021. Q4 earnings slightly beat estimates, but revenue declined 9% year-on-year, with poor forward visibility and weak guidance for Q1 2025. Management's new 2024 targets are more achievable, but investor confidence remains low due to past underperformance and modest valuation.

These Analysts Revise Their Forecasts On NXP Semiconductors After Q4 Results
These Analysts Revise Their Forecasts On NXP Semiconductors After Q4 Results
These Analysts Revise Their Forecasts On NXP Semiconductors After Q4 Results
NXP
benzinga.comFebruary 5, 2025

NXP Semiconductors NV NXPI reported better-than-expected fourth-quarter financial results after Monday's closing bell.

Chipmaker NXP forecasts downbeat first-quarter revenue on soft demand
Chipmaker NXP forecasts downbeat first-quarter revenue on soft demand
Chipmaker NXP forecasts downbeat first-quarter revenue on soft demand
NXP
reuters.comFebruary 3, 2025

NXP Semiconductors forecast its first-quarter revenue below analysts' estimates on Monday, in a sign of sluggish demand for its chips from industrial and automotive customers.

NXP Semiconductors Reports Fourth Quarter and Full-Year 2024 Results
NXP Semiconductors Reports Fourth Quarter and Full-Year 2024 Results
NXP Semiconductors Reports Fourth Quarter and Full-Year 2024 Results
NXP
globenewswire.comFebruary 3, 2025

EINDHOVEN, The Netherlands, Feb. 03, 2025 (GLOBE NEWSWIRE) -- NXP Semiconductors N.V. (NASDAQ: NXPI) today reported financial results for the fourth quarter and full-year, which ended December 31, 2024. “NXP delivered full-year 2024 revenue of $12.61 billion, a decrease of 5 percent year-on-year. In the fourth quarter, revenue was $3.11 billion, a decrease of 9 percent year-on-year, modestly above the mid-point of our guidance range. In review, NXP delivered resilient results throughout 2024, reflecting solid execution, consistent gross margin, and healthy free cash flow generation despite a challenging market environment. We rigorously focus on managing what is in our control, to navigate a soft landing while executing our growth strategy,” said Kurt Sievers, NXP President and Chief Executive Officer.